Leidos Names Steven Russell Senior Vice President For Sales And Strategic Accounts

Russell to Manage the Company's Commercial Health Business Development Pipeline

News provided by

Dec 08, 2014, 07:50 ET

RESTON, Va., Dec. 8, 2014 /PRNewswire/ -- Leidos (NYSE: LDOS) a national security, health, and engineering solutions company, today announced the appointment of Steven Russell as senior vice president for sales and strategic accounts of Leidos Health, effective December 1, 2014.

Russell will be responsible for the sales and account management teams, who will partner with existing and new accounts to achieve client satisfaction and drive business development opportunities for hospitals and health systems. He will also be responsible for achieving the organization's revenue goals, developing an optimal account management strategy, and retaining a metric-driven sales organization.

Prior to Leidos, Russell was the senior vice president of corporate development at Quantros Corporation, where he was responsible for SaaS-based products for patient safety, quality management, and analytics as well as new market and business development activities, consulting services, product strategy, and strategic partnerships. He has also held senior sales and corporate development roles at companies such as Cerner, Aperio Technologies, Quadramed, HealthScribe, and Compucare.

"With more than 20 years of executive sales leadership across the healthcare industry, Steven brings significant experience and knowledge of the Health IT market," said Leidos Health President Steve Comber. "His leadership credentials will have an immediate impact on our commercial health business, and his Health IT acumen will have an enduring impact on the services we offer our customers."

Russell earned a bachelor's degree from Indiana University and attended Harvard Business School's "Finance for Senior Executives" program. He has been a member of the American College of Healthcare Executives, the Healthcare Information and Management Systems Society (HIMSS), the Digital Pathology Association, and the Northern Virginia Technology Council.

About Leidos Health
Leidos Health is a leading healthcare IT consulting firm with deep clinical and technical expertise to support our customers in selecting, implementing, and optimizing information technology investments. Leidos Health offers a comprehensive range of technology services for health care providers - from vendor selection, strategy, design, implementation, and optimization, across all major electronic medical record systems. Our professional services help providers meet regulatory requirements, optimize technology for their clinical workflow, improve collections and reduce receivables, and keep data safe. For more information, visit www.leidoshealth.com.

About Leidos
Leidos is a FORTUNE 500^® science and technology solutions leader working to address some of the world's toughest challenges in national security, health and engineering. The Company's 20,000 employees support vital missions for our government and the commercial sector, develop innovative solutions to drive better outcomes and defend our Nation's digital and physical infrastructure from 'new world' threats. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $5.77 billion for its fiscal year ended January 31, 2014 after giving effect to the spin-off of the company's technical services and information technology business. For more information, visit www.Leidos.com.

Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company's Annual Report on Form 10-K for the period ended January 31, 2014, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.